logo-loader
Collagen Solutions PLC

Collagen Sol PLC - China update

RNS Number : 9337E
Collagen Solutions PLC
15 February 2018
 

 

15 February 2018

Collagen Solutions Plc

(the "Company" or the "Group")

 

China Update

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen and tissue components for use in regenerative medicine, including orthopaedic, dental, wound care, and cardiovascular applications, provided an update on its Chinese operations.

Over the course of 2017 the Company established a solid foundation in terms of its China market entry strategy through its joint venture with China Resources & Investment Limited (known as "Cre8ive"), who have been instrumental in securing the Company's product import pathway into China and securing initial customers.

Key highlights of these accomplishments include:

·     Obtaining import clearances for Collagen Solutions' biomaterials from both UK and New Zealand,

·     Completing a joint market assessment for collagen medical products identifying over 4 billion RMB end-market opportunity1,

·     Developing an initial pipeline of specific and attractive customer opportunities, and 

·     Closing the first two supply agreements with Chinese customers, currently in the pre-CFDA submission phase

Following these promising milestones, and a detailed review of opportunities and resource needs going forward, Collagen Solutions has determined a plan for next steps to maximise future market opportunities.

Collagen Solutions engaged a new Shanghai-based firm specialising in the matching of foreign medical device companies with first-tier distributors across China. In addition, Collagen Solutions and Cre8ive have mutually agreed to terminate the joint venture such that Collagen Solutions now owns 100% of the Chinese subsidiary, whilst Cre8ive will continue to provide in-country support services to Collagen Solutions. This new arrangement will allow the Company more flexibility in engaging with and providing technical support to commercial partners in China to take advantage of opportunities within this important territory.

Commenting on this announcement, Jamal Rushdy said: "We are pleased with our initial progress in China and appreciative of Cre8ive's efforts in securing an effective importation pathway for our materials business and securing our first two customers. This new arrangement is critical to the development of Collagen Solutions' sales and distribution channels within China and is well aligned with the 'Chinese culture' of successfully engaging with partners. We are optimistic regarding the potential to realise growth from this significant market and look forward to providing further updates as they develop."

 

 

Collagen Solutions Plc
Jamal Rushdy, Chief Executive Officer
Hilary Spence, Chief Financial Officer
Lisa Baderoon, Head of Investor Relations




Tel: 07721 413 496 or 
lisa.baderoon@collagensolutions.com

Cenkos Securities plc (Nominated Adviser and Broker)
Stephen Keys
Steve Cox

Tel: 0207 397 8900

Walbrook PR
Anna Dunphy

Tel: 020 7933 8780 or collagen@walbrookpr.com
Mob: 07900 608 002

 

 

 



1 Internal Company research and Med Qiao Group LLC


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDGGUWAPUPRGRC
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: Vaccines and EU package lift FTSE 100

Headlines from the Proactive UK newsroom. The FTSE 100 was in better heart as yesterday’s vaccine news and €750bn EU bail-out package helped sentiment. The blue-chip index rose 43 points to 6,305. Grocery tills were their busiest ever over the past 12 weeks according to market research...

on 21/7/20

3 min read